Aripiprazole
Product Images NDC 17856-0100

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Case Label)

This label is for Aripiprazole Tablets, USP, 15 mg per tablet, from ATLANTIC BIOLOGICALS CORP. It indicates the dosage strength as 15mg per tablet and a package quantity of 100 tablets. The label includes storage instructions (20°-25°C, excursions permitted between 15°-30°C), barcode, QR code, and expiration date of 09/23/24.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A forest plot chart illustrating the fold change in pharmacokinetic parameters (AUC, Cmax, DW/DRP) for various drugs when administered with interacting drugs, compared to a reference without interacting drugs. The vertical axis lists interacting drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The horizontal axis shows the fold change with 90% confidence intervals, ranging approximately from 0.5 to 3.0.*

FDA Label Image

Aripiprazole-fig-6.jpg (Aripiprazole Fig 6)

A Kaplan-Meier plot showing the proportion of subjects with relapse over time following randomization for Aripiprazole versus placebo. The x-axis represents days from randomization up to 182 days, and the y-axis represents the proportion with relapse. Lines compare Aripiprazole (solid) and placebo (dashed), with subject numbers at risk indicated below the timeline.*

FDA Label Image

Aripiprazole-fig-9.jpg (Aripiprazole Fig 9)

A line graph titled 'Change in YGTSS Total TIC Score from Baseline' depicting least-squares mean change in YGTSS total TIC score over 8 weeks of treatment. It compares Aripiprazole Low dose, Aripiprazole High dose, and Placebo groups, showing greater score reductions for Aripiprazole groups than placebo over time.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

A line graph comparing the proportion of relapse over days from randomization between Aripiprazole and placebo groups. The y-axis shows the proportion with relapse from 0 to 1, while the x-axis shows days from randomization up to 182 days. The graph includes a risk table indicating the number of subjects at risk for each group at various time points.*

FDA Label Image

Aripiprazole-figure1.jpg (Aripiprazole Figure1)

A pharmacokinetic chart showing the effect of various drugs on Aripiprazole's exposure measured as AUC and Cmax. It presents fold changes and 90% confidence intervals for CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs relative to a reference without interacting drugs. The x-axis represents the change relative to the reference, ranging approximately from 0.5 to 3.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic chart illustrating the effect of various drugs on the fold change of dehydro-aripiprazole levels and their 90% confidence intervals. The chart displays changes in AUC and Cmax for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) relative to reference aripiprazole without interacting drugs.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic plot titled 'Aripiprazole Fold Change and 90% CI' displaying fold changes in AUC and Cmax for various special populations relative to reference groups. Categories include CYP2D6 metabolism status, gender, age, hepatic impairment severity, and severe renal impairment, with fold changes and confidence intervals plotted along an x-axis ranging from 0.5 to 3.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% Confidence Interval' showing pharmacokinetic changes in AUC and Cmax relative to reference under various conditions: CYP2D6 metabolism status (poor vs. extensive), gender (female vs. male), age groups (18 to 64 vs. >65 years), hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment. Horizontal bars represent 90% confidence intervals around fold change values plotted on a logarithmic scale from 0.5 to 3.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of aripiprazole, showing its characteristic molecular configuration including two chlorine atoms, a piperazine ring, and a quinolinone moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.